Cangrelor
Platelet Aggregation Inhibitors Excl. Heparin
Sold as Kengrexal
- Drug class
- Platelet Aggregation Inhibitors Excl. Heparin
- Availability
- See label
- Routes
- Intravenous
- Markets covered
- 3
- Products on record
- 3
Overview
Cangrelor is an active pharmaceutical ingredient in the Platelet Aggregation Inhibitors Excl. Heparin group (B01AC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 1 | April 10, 2026 |
| EU European Union | EMA | 1 | March 10, 2026 |
| CA Canada | Health Canada | 1 | March 22, 2025 |
GBUnited Kingdom· MHRA
1 product
Uses
Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.
How to take
EUEuropean Union· EMA
1 product
Uses
Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.
How to take
CACanada· Health Canada
1 product
Uses
KENGREXAL (cangrelor) is indicated for reducing the risk of thrombotic cardiovascular events (periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST)) in patients with coronary artery disease undergoing percutaneous coronary intervention who have not been treated with an oral P2Y12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor.
1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. 2 Geriatrics Geriatrics (≥75 years of age): No overall differences in safety or effectiveness were observed between the geriatric population and patients <75 years of age.
How to take
Drug interactions
Known interactions involving Cangrelor. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PLGB088290187 · revised April 10, 2026
- [2]European Medicines Agency · EMEA/H/C/003773 · revised March 10, 2026
- [3]Health Canada (DPD) · 02534622 · revised March 22, 2025
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.